Navigation Links
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
Date:11/14/2012

CRANBURY, N.J., Nov. 14, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its first quarter ended September 30, 2012. 

Recent Highlights
On July 3, 2012, Palatin closed on a private placement of 3,873,000 shares of its common stock, Series A 2012 warrants to purchase up to 31,988,151 shares of its common stock, and Series B 2012 warrants to purchase up to 35,488,380 shares of its common stock. Aggregate gross proceeds to Palatin were $35,000,000, with net proceeds, after deducting offering expenses, of $34,407,446.

On September 27, 2012, at a special meeting Palatin stockholders voted to increase its authorized common stock from 100,000,000 to 200,000,000 shares, and Palatin filed a certificate of amendment with the Secretary of State of Delaware the same day. This satisfied certain contractual obligations relating to the Series B 2012 warrants in its 2012 private placement, so that interest will not be payable on the value of the Series B 2012 warrants and Palatin will not be required to redeem the Series B 2012 warrants for failure to increase the number of authorized shares.

On November 8, 2012, Palatin reported positive top-line results, including the successful achievement of statistical significance for the primary endpoint and key secondary endpoints in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD). The primary endpoint data analysis of 327 pre-menopausal women with female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD), or a combination of both disorders, the most common types of FSD, demonstrate that women taking bremelanotide showed clinically meaningful and statistically significant increases
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... -- According to the International Atomic Energy Agency ... from terrorists acquiring sufficient quantities of plutonium or ... nuclear explosive device. The IAEA also notes that ... gram-level quantities, which can be challenging to detect ... new study appearing this week in the ...
(Date:7/10/2014)... 2014 Using microscopic polymer light resonators that ... at MIT,s Quantum Photonics Laboratory have developed new ... parts-per-billion range. Optical sensors are ideal for detecting ... ratio, compact, lightweight nature, and immunity to electromagnetic ... been developed before, the MIT team conceived an ...
(Date:7/10/2014)... of psychiatric disorders has been extremely challenging because there ... are insufficient to cause disease. Now investigators reporting in ... Cell Stem Cell describe a strategy that ... with other risk factors or environmental exposures to affect ... a genetic variant that may predispose individuals to schizophrenia. ...
(Date:7/10/2014)... batteries that power our laptops and electric vehicles could ... charge with the help of a sponge-like silicon material. ... the graphite traditionally used in one of the battery,s ... energy storage capacity of graphite. A paper describing the ... today in Nature Communications . , "Silicon has ...
Breaking Biology Technology:Sensitive detection method may help impede illicit nuclear trafficking 2Swell new sensors 2New strategy could uncover genes at the root of psychiatric illnesses 2Silicon sponge improves lithium-ion battery performance 2Silicon sponge improves lithium-ion battery performance 3
... adison, Wis. - Third Wave Technologies, Inc. ... a share, for the second quarter of 2006, but robust ... upward in a key market. , ,Third Wave, which develops ... that revenue rose by 15 percent for the quarter ended ...
... Madison, Wis. - A United States Air Force contract ... not only provide a Madison aerospace research and product development ... it to propel something much larger. , ,The U.S. ... Orbital Technologies Corp. (Orbitec) for the development of ...
... - Thanks to a classified contract from the ... company headquartered here, reported record revenues and earnings for ... the closing of its manufacturing facility in England. , ... of lower-than-expected earnings in the fourth quarter, which caused ...
Cached Biology Technology:Third Wave reports another loss, stronger sales 2Third Wave reports another loss, stronger sales 3Orbitec will use $25 million Air Force contract to make small launch vehicle 2Defense contract helps Plexus gain record profits 2
(Date:7/11/2014)... the Department of Energy,s Oak Ridge National Laboratory ... R&D Magazine in recognition of the year,s top ... tremendous value of our National Labs," said Secretary ... the National Labs continues to help our nation ... and technological innovations necessary to remain globally competitive." ...
(Date:7/11/2014)... The University of Chicago is creating a new ... at the University,s Institute for Molecular Engineering and ... million donation from the Millicent and Eugene Bell ... will reside within the Institute for Molecular Engineering. ... research project at the MBL,s Eugene Bell Center ...
(Date:7/11/2014)... The Chinese University of Hong Kong, BGI and other ... to salt tolerance, with implication for improving this important ... online in Nature Communications provides an effective ... , Soybean is an important crop for the world. ... less genetic diversities than their wild counterparts. Among the ...
Breaking Biology News(10 mins):ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4New professorship in tissue engineering links molecular engineering, marine biology 2BGI reports a novel gene for salt tolerance found in wild soybean 2
... the University of Leeds are developing methods of helping ... chemicals such as vinegar. , The harmful chromium ... from former textiles factories, smelters, and tanneries have been ... problems with the kidneys, liver, lungs and skin. , ...
... but researchers in China have discovered that chicken manure can ... in the International Journal of Environment and Pollution ... 50% more crude oil than soil lacking the guano. ... University, China, point out that contamination of soil by crude ...
... comes to solving complex problems, Geoffrey von Maltzahn, MIT ... solutions. Finding inspiration in systems that evolution has produced, ... society,s biggest challenges: improving tumor detection and therapeutic delivery ... patients. Today, the 28-year-old Ph.D. candidate in ...
Cached Biology News:Cleansing toxic waste -- with vinegar 2Fowl soil additive breaks down crude oil 2MIT student develops new innovations to selectively kill cancer cells 2MIT student develops new innovations to selectively kill cancer cells 3MIT student develops new innovations to selectively kill cancer cells 4
Mouse monoclonal [3G131] to Desmoglein 1 ( Abpromise for all tested applications). entrezGeneID: 1828 SwissProtID: Q02413...
Mouse monoclonal [2D7/1] to E.coli LPS ( Abpromise for all tested applications). Antigen: Tissue / cell preparation: Escherichia coli J5 cells....
COMING SOON: Anti-Mouse C5/C5b, Clone BB5.1. Monoclonal Antibody...
KAI 1 (G-2)...
Biology Products: